Антифосфолипидный синдром - часть 50

205

243. Picillo U, Migliaresi S, Marciolis MR,

Longobardo A, La Palombara F, Tirri G. Longi
tudinal survey of anticardiolipin antibodies in
systemic lupus erythematosus. Relationship with
clinical manifestations and disease activity in an
Italian series. Scand J Rheumatol 1992; 21:
271—276.

244. Petri M. Musculoskeletal complication of

systemic lupus erythematosus in the Hopkins
Lupus Cohort: an update. Arthritis Care Res
1995; 18: 137—145.

245. Houissau FA, N'ZeusseuToukap A,

Depresseu XG, et al. Magnetic resonance imag
ingdetected, avascular necrosis in systemic lupus
erythematosus: lack of correlation with antiphos
pholipid antibodies. Br J Rheumatol 1998; 37:
448—453.

246. Nagasawa K, Ishii Y, Mayumi T et al.

Avascular necrosis of bone in systemic lupus
erythematosus: possible role of haemostatic
abnormalities. Ann Rheum Dis 1989; 48: 672—
676.

247. Mont MA, Glueck CJ, Pacheco IH, Wang

P, Hungerford DS, Petri M. Risk factors for
osteonecrosis in systemic lupus erythematosus. J
Rheumatol 1997; 24: 654—662.

248. Jones LC, Mont MA, Lr TB, et al. Proco

agulants and osteonecrosis. J Rheumatology
2003; 30: 783—791.

249. Tektonidou MG, Malagari K, Vlachoyian

nopoulos PG, et al. Asympomatic avascular
necrosis in patients with primary antiphospholipid
syndrome in the absence of corticosteroid use.
Arthritis Rheum 2003; 48: 732—736.

250. Lockwood CJ, Schur PH. Clinical mani

festations and diagnosis of the antiphospholipid
antibody syndrome in pregnancy. UpToDate
2002; 11.1.

251. InfanteRivard C, David M, Gauthier R,

Rivard GE. Lupus anticoagulants, anticardiolipin
antibodies, and fetal loss. N Engl J Med 1991;
325: 1063.

252. Oshiro BT, Silver RM, Scott JR, et al.

Antiphospholipid antibodies and fetal death.
Obstet Gynecol 1996; 87: 489.

253. Hornstein MD, Davis OK, Massey JB, et

al. Antiphospholipid antibodies and in vitro fertil
ization success: a metaanalysis. Fertil Steril
2000; 73: 330.

254. Vivaldi P, Rossetti G, Galli M, Finazzi G.

Severe bleeding due to acquired hypoprothrom
binemialupus anticoagulant syndrome. Case
report and review of literature. Haematologica
1997; 82: 345.

255. Erkan D, Bateman H, Lockshin MD. Lu

pus anticoagulanthypoprothrombinemia syn
drome associated with systemic lupus erythemato
sus: report of 2 cases and review of literature.
Lupus 1999; 8: 560.

256. McNeil HP, Chesterman CN, Krilis SA.

Immunology and clinical importance of anti
phospholipid antibodies. Adv Immunol 1991;
49:193.

257. Harris EN, Gharavi AE, Hegde U, et al.

Anticardiolipin antibodies in autoimmune throm
bocytopenic purpura. Br J Haematol 1985; 59:
231.

258. DizKucukkaya R, Hacihanefioglu A,

Yenerel M, et al. Antiphospholipid antibodies
and antiphospholipd syndrome in patients pre
senting with immune thrombocytopenic purpura:
A prospective cohort study. Blood 2001; 98:
1760.

259. Lee T, von Scheven E, Sandborg C. Syste

mic lupus erythematosus and antiphospholipid
syndrome in children and adolescent. Curr Opin
Rheumatol 2001; 13: 415—421.

260. Насонов ЕЛ, Рябова ТВ, Шпитонкова

ОЛ, Александрова ЕН. Антифосфолипидный
синдром в педиатрии. Детская ревматология
1995; 1: 67—73.

261. Ravelli A, Caporali R, Di Fuccia G, et al.

Anticardiolipin antibodies in pediatric systemic
lupus erythematosus. Arch Pediatr Adolesc Med
1994; 148: 398—402.

262. Seaman DE, Londjino AV, Jr, Kwoh CK,

et al. Antiphospholipid antibodies in pediatric sys
temic lupus erythematosus. Pediatrics 1995; 96:
1040—1045.

263. Gattorno M, Buoncompagni A, Molinari

AC, et al. Antiphospholipid antibodies in paedi
atric systemic lupus eruthematosus, juvenile
chronic arthritis and overlap syndromes: SLE
patients wuth both lupus anticoagulant and
hightitre anicardiolipin antibodies are at risk
for clinical manifestations related to the
antiphospholipid syndrome. Br J Rheumatol
1995; 34: 873—881.

ГЛАВА 7. Клинические проявления антифосфолипидного синдрома

Насонов Е.Л. Антифосфолипидный синдром

206

264. Shergy WJ, Kredich DW, Pisetsky DS.

The relationship of anticardiolipin antibodies to
disease manifwestations in pediatric systemic
lupus erythematosus. J Rheumatol 1988; 15:
1389—1394.

265. Berube C, Mitchell L, Silverman E, et al.

The relationship of anticardiolipin antibodies to
thromboembolic events in pediatriv patients with
systemic lupus erythematosus: a crosssectional
study. Pediatr Res 1998; 44: 351—358.

266. von Scheven EY, Glidden DV, Elder ME.

Anti

β

2

glycoprotein I antibodies in pediatric

systemic lupus erythematosus and antiphospho
lipid syndrome Arthritis Rheum (Arthritis Care
Res) 2002; 47: 414—420.

267. Falcini F, Tacetti G, Trapani S, et al.

Primary antiphospholipid syndromeL a report of
two pediatric cases. J Rheumatology 1991; 18:
1085—1087.

268. Von Landenberg P, Lehmann HW, Knoll

A, et al. Antiphospholipid antibodies in pediatric
and adult patients with rheumatic disease are
associated with parvovirus B19 infection. Arthritis
Rheum 2003; 48: 1939—1947.

269. Shpitonkova OV, Ryabova TV, Alexan

drova EN, Nasonov EL. Antiphospholipid syn
drome (APS) in children with SLE. III European
Conference on Systemic Lupus Erythematosus,
1996, Pisa, Italy, 47 (126 abst).

270. Chang DM, Chang CC, Kuo SY, Chu

SJ, Chang ML. Hormonal profiles and
immunological studies of male lupus in Taiwan.
Clin Rheum 1999; 18: 158—162.

271. Folomeev M, Afanasjev W, Alekberova Z.

Survival prognostic factors revealed from initial
features of systemic lupus erythematosus in male
patients. III Intern. Conference on SLE, London,
Lupus 1992; 1 (Suppl 1): 122 (аbst).

272. Masi AT, Kaslow RA. Sex effects in sys

temic lupus erythematosus: a clue to pathogenesis.
Arthr Rheum 1978; 21: 480—484.

273. Kaufman LD, GomezReino JJ,

Heinicke MH, Gorevic P.D. Male lupus: retro
spective analysis of the clinical and laboratory
features of 52 patients, with review of the liter
ature. Sem Arthr Rheum 1989; 18, 3, 189—
197.

274. Koh WH, Fong KY, Boey ML, Feng

PH. Systemic lupus etythematosus in 61 orien

tal males. A study of clinical and laboratory
manifestations. Br J Rheum 1994; 33, 339—
342.

275. Miller MH, Urowitz MB, Gladman D.D.,

Killinger D.W. Systemic lupus erythematosus in
males. Medicine (Baltimore) 1983; 62, 5, 327—
334.

276. Sthoeger ZM, Geltner D, Rider A, Bent

wich Z. Systemic lupus erythematosus in 49 Israel
males: a retrospective study. Clin Exp Rheum
1987; 5: 233—240.

277. AlarconSegovia D. Antiphospholipid syn

drome in SLE. Lupus 1992; 1, (Suppl 1): 13
(abst).

278. Насонов ЕЛ, Алекберова ЗС, Клюквина

НГ, Александрова ЕН, Саложин КВ, Ле Тон
гез М, Юну П. Антифосфолипидный синдром
при системной красной волчанке у мужчин.
Клин. медицина, 1996; 4: 18—22.

279. Asherson RA. The "primary" antiphospho

lipid syndrome. J Rheumatol 1988; 15: 742—
1746.

280. AlarconSegovia D, SanchezGuerrero J.

Primary antiphospholipid syndrome J Rheumatol
1989; 16: 482—488.

281. MackworthYoung CG, Loizou S,

Walport MJ. Primary antiphospholipid syn
drome: features with raised anticardiolipin anti
bodies and other disorders. Ann Rheum Dis
1989; 48: 362—367.

282. Mujic F, Cuadrado MJ, Lloyd M, et al.

Primary antiphospholipid antibody syndrome
evolving into systemic lupus erythematosus. J
Rheumatol 1995; 22: 1589.

283. Sneddon IB. Cerebrovascular lesions and

livedo reticularis. Br J Dermatol 1965; 77: 180—
185.

284. Kalashnikova LA, Nasonov E.L,

Kushekbaeva AE, Gracheva LA. Anticardiolipin
antibodies in Sneddon`s syndrome. Neurology
1990; 40: 464—467.

285. Kalashnikova LA, Nasonov EL, Stoyano

vich LZ, et al. Sneddon`s syndrome and the pri
mary antiphospholipid syndrome. Cerebrovas
cular Dis 1994; 4: 76—82. 

286. Kalashnikova LA, Nasonov EL, Borisenko

VV, et al. Sneddon`s synrome: cardiac pathology
and antiphospholipid antibodies. Clin Exp
Rheumatol 1991; 9: 357—361.

207

287. Asherson R.A. The catastrophic antiphospho

lipid syndrome J Rheumatol 1992; 19: 508—512.

288. Asherson RA, Cervera R, Font J. Multio

rgan thrombotic disorders in systemic lupus erythe
matosus: a common link? Lupus 1992; 1: 199203.

289. Harris EN, Bos K. An acute disseminated

coagulopathyvascolopsathy with the antiphos
pholipid syndrome. Arch Int Med 1991; 151:
231—233.

290. Ingram SB, Goodnight SH, Bennet RM.

An unusual syndrome of devasting noninflam
matory vasculopathy associated with anticardi
olipin antibodies a report of two cases Arthr
Rheum 1987; 30: 1167—1171.

291. Piette JC, Cervera R, Levy RA, Nasonov

EL, Shoenfeld Y. The catastrophic Antiphosp
holipid syndrome — Asherson`s syndrome. Ann
Med Intern 2003.

ГЛАВА 7. Клинические проявления антифосфолипидного синдрома

Антитела к фосфолипидам (аФЛ) представляют собой семейство ау

тоантител, распознающих антигенные детерминанты анионных и нейт

ральных фосфолипидов и комплексные эпитопы, образующиеся в про

цессе взаимодействия фосфолипидов и фосфолипидсвязывающих бел

ков

1

(таблица 8.1). После того как было установлено, что аФЛ реагиру

ют не с фосфолипидами, а с фосфолипидсвязывающими белками, неко

торые авторы предпочитают использовать термин "антитела к фосфоли

пид

Таблица 8.1. Спектр антител, выявляемых в сыворотке больных АФС

2

•• аФЛ, выявляемые при реакции Вассермана 

(ложноположительная реакция Вассермана)

• аФЛ, выявляемые при определении аКЛ иммуноферментным методом

к кардиолипину

к 

β

2

ГПI

к ПТ

к аннексину V

к другим ФЛсвязывающим белкам (?)

208

глава 8

К

К Л

Л И

И Н

Н И

И Ч

Ч Е

Е С

С К

К О

О Е

Е    З

З Н

Н А

А Ч

Ч Е

Е Н

Н И

И Е

Е   

А

А Н

Н Т

Т И

И Ф

Ф О

О С

С Ф

Ф О

О Л

Л И

И П

П И

И Д

Д Н

Н Ы

Ы Х

Х    А

А Н

Н Т

Т И

И Т

Т Е

Е Л

Л